Sex, age, and time to cardioversion. Risk factors for cardioversion of acute atrial fibrillation from the FinCV study

Annals of Medicine

Volumn 49, Issue 3, 2017, Pages 254-259

  Bah, Aissa ^a   Nuotio, Ilpo ^b   Grönberg, Toni ^b   Ylitalo, Antti ^b,c   Airaksinen, K E Juhani ^b   Hartikainen, Juha E K ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c SATAKUNTA CENTRAL HOSPITAL   (Finland)

Author keywords

Age; atrial fibrillation; electrical cardioversion; female sex; time to cardioversion

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTICOAGULANT AGENT;

ADULT; AGE; AGED; ARTICLE; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEW-ONSET ATRIAL FIBRILLATION; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOEMBOLISM; TIME TO TREATMENT; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VASCULAR DISEASE; ACUTE DISEASE; ATRIAL FIBRILLATION; COMPLICATION; EPIDEMIOLOGY; FINLAND; INCIDENCE; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR;

ACUTE DISEASE; AGE FACTORS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; FEMALE; FINLAND; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; THROMBOEMBOLISM; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 85007420776     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.1080/07853890.2016.1267869     Document Type: Article

References (18)

1. Camm A, Lip G, De Caterina R, Savelieva I, Atar D, Hohnloser S, et al. 2012 guidelines for the management of atrial fibrillation. The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2719–49.
2. Bushnell C, McCullough L, Awad I, Chireau M, Fedder W, Furie K, et al. Guidelines for the prevention of stroke in women:a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:1545–88.
3. Abraham J, Larson J, Chung M, Curtis A, Lakshminarayan K, Newman J, et al. Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation? Am J Med. 2013;126:1148–53.
4. Friberg L, Benson L, Rosenqvist M, Lip G., Assessment of female sex as a risk factor in atrial fibrillation in Sweden:nationwide retrospective cohort study. BMJ. 2012;344:3522.
5. Olesen J, Lip G, Hansen M, Hansen P, Tolstrup J, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation:nationwide cohort study. BMJ. 2011;342:d124.
6. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics—2008 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:25–146.
7. Kleemann T, Becker T, Strauss M, Schneider S, Seidl K., Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation, <48 hours undergoing cardioversion:value of transesophageal echocardiography to guide cardioversion. J Am Soc Echocardiogr. 2009;22:1403–8.
8. Airaksinen J, Grönberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation. The FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013;62:1187–92.
9. Nuotio I, Hartikainen J, Grönberg T, Biancari F, Airaksinen J., Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014;312:647–9.
10. Cappato R, Ezekowitz MD, Klein L, Camm J, Chang-Sheng M, Le Heuzey JY, on behalf of the X-VeRT Investigators, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35:3346–55.
11. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation:an analysis of patients undergoing cardioversion. Circulation. 2011;123:131–6.
12. Flaker G, Lopes R, Al-Khatib S, Hermosillo A, Hohnloser S, Tinga B, for the ARISTOTLE Committees and Investigators, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation insights from the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63:1082–7.
13. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS:the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;37:2893–962.
14. Azoulay L, Dell’Aniello S, Simon T, Renoux C, Suissa S., Initiation of warfarin in patients with atrial fibrillation:early effects on ischaemic strokes. Eur Heart J. 2014;35:1881–7.
15. Linhart M, Lewalter T., Elektrische und pharmakologische Frühkardioversion von Vorhofflimmern [Electrical and pharmacological strategies for early cardioversion of atrial fibrillation]. Herzschrittmacherther Elektrophysiol. 2006;17:81–8.
16. Sohara H, Amitani S, Kurose M, Miyahara K., Atrial fibrillation activates platelets and coagulation in a time-dependent manner:a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29:106–12.
17. Rienstra M, Van Veldhuisen D, Hagens V, Ranchor A, Veeger N, Crijns H, et al. Gender-related differences in rhythm control treatment in persistent atrial fibrillation:data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol. 2005;46:1298–306.
18. Grönberg T, Hartikainen J, Nuotio I, Biancari F, Vasankari T, Nikkinen M, et al. Can we predict the failure of electrical cardioversion of acute atrial fibrillation? The FinCV study. Pacing Clin Electrophysiol. 2014;38:368–75.